A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-30. Anything still debated is marked as such rather than presented as settled.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
=== Drug repurposing === Chemoproteomics is at the forefront of drug repurposing. This is particularly relevant in the era of COVID-19, which saw a dire need to rapidly identify FDA approved drugs that have antiviral activity. In this context, a phenotypic screen is usually employed to identify drugs with a desired effect in vitro, such as inhibition of viral plaque formation. If a drug produces a positive test, the next step is to determine whether it is acting on a known or novel target. Chemoproteomics is thus a follow-up to phenotypic screening. In the case of COVID-19, Friman et al investigated off-target effects of the broad-spectrum antiviral Remdesivir, which was among the first repurposed drugs to be used in the pandemic. Remdesivir was tested via thermal proteome profiling in a HepG2 cellular thermal shift assay, along with the controversial drug hydroxychloroquine, and investigators discovered TRIP13 as a potential off-target of Remdesivir.
== Structure and available forms == α-Bungarotoxin consists of an 8 kDa, single polypeptide chain that contains 74 amino acid residues. This polypeptide chain is cross-linked by five disulfide bridges, categorizing the α-bungarotoxin as a type II α-neurotoxin within the three-finger toxin family. These disulfide bridges are formed between the specific cysteine residues and are important for the stability and function of the toxin. Furthermore, α-bungarotoxin contains ten residues of half-cysteine per molecule. The specific arrangements of disulfide bridges formed by these cysteine residues result in the 11-ring structure within the toxin molecule. This 11-ring structure is particularly essential for the toxin interactions with the target receptors and modulation of the neurotransmission at the neuromuscular junction. The amino acid sequence of the α-bungarotoxin contains a high frequency of homodipeptides, with ten pairs present where serine and proline dipeptides occur twice in the sequence. The active site of the toxin is located in the region from position 24 to position 45 within the sequence. There are some key amino acids commonly found in this region that include cysteine, arginine, glycine, lysine and valine. As previously mentioned, cysteine is crucial for the disulfide bridges formation in proteins. Arginine and lysine can participate in interactions with negatively charged molecules or residues, so they may play a role in the binding to specific receptors or substrates. Glycine may contribute to the flexibility and conformational dynamics of the α-bungarotoxin.
(i) Opium, opiates, derivatives of opium and opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation. Such a term does not include the isoquinoline alkaloids of opium. (ii) Poppy straw and concentrate of poppy straw. (iii) Coca leaves, except coca leaves and extracts of coca leaves from which cocaine, ecgonine and derivatives of ecgonine or their salts have been removed. (iv) Cocaine, its salts, optical and geometric isomers, and salts of isomers. (v) Ecgonine, its derivatives, their salts, isomers, and salts of isomers. (vi) Any compound, mixture, or preparation which contains any quantity of any of the substances referred to in paragraphs (b)(31)(i) through (v) of this section.
An example daily menu can consist of: Breakfast: curds and nuts, mashed potatoes with nuts, apple-quince chip sticks, sugarless coffee, and vitamins Lunch: jellied pike perch, borscht with meat, goulash with buckwheat, bread, black currant juice, sugarless tea Supper: rice and meat, broccoli and cheese, nuts, tea with sugar Second supper: dried beef, cashew nuts, peaches, grape juice Sweden: Swedish astronaut Christer Fuglesang was not allowed to bring reindeer jerky with him on board a shuttle mission as it was "weird" for the Americans so soon before Christmas. He had to go with moose instead. France: In April 2021 French astronaut Thomas Pesquet brought with him on SpaceX Crew-2 a few signature French dishes to share with his fellow astronauts: space safe version of beef bourguignon, einkorn risotto, and crêpe Suzette. Poland: Specially for IGNIS, the first Polish mission to the International Space Station, scheduled for spring 2025 and featuring ESA project astronaut Dr. Sławosz Uznański-Wiśniewski, the commercial company LYOFOOD, in collaboration with the European Space Agency, developed a Bonus Food menu of freeze-dried signature Polish meals. The menu includes pierogi stuffed with cabbage and mushrooms, tomato soup with noodles, Polish “leczo” stew with buckwheat, and apple crumble for dessert. The recipes for the first three dishes were developed by renowned Polish chef and restaurateur Mateusz Gessler, while the apple crumble was selected from LYOFOOD’s dessert offerings. Usually, freeze-dried food rehydrates by absorbing added water.
Sources: en.wikipedia.org
== June 7, 1915 (Monday) == Battle of Hébuterne — The French 2nd Army attacked German positions around Hébuterne, France to support the 10th Army efforts further north at Artois. French troops were able to overrun the first two German lines during the opening day. The Dardanelles Committee met in London decided to reinforce the Mediterranean Expeditionary Force of General Ian Hamilton with three divisions from Kitchener's Army in an attempt to reinvigorate the Gallipoli campaign. The first German Army Zeppelin airship was destroyed in air-to-air combat by British pilot Reginald Warneford of No. 1 Squadron over Ghent, Belgium. The airship crashed in Sint-Amandsberg, Belgium, killing one person on the ground and all but one of the crew. Warneford received the Victoria Cross for the action. The LZ 38, the first Zeppelin P Class airship of the Imperial German Army, was destroyed when British planes bombed the shed it was housed in near Evere, Belgium. The first airship flew out of Friedrichshafen-Löwental airfield near Friedrichshafen, Germany. Born: Dominic Bruce, British air force officer, member of the No. 9 and No. 214 Squadrons during World War II, noted escapee from German POW camp Oflag IV-C at Colditz Castle, recipient of the Order of the British Empire, Order of St. Gregory the Great, Military Cross, and Air Force Medal; in Hebburn, England (d. 2000) Graham Ingels, American comic book artist, best known for his work for EC Comics; in Cincinnati, United States (d.
SUMOylation Also sumoylation. A type of post-translational modification in which a SUMO protein is conjugated to a polar residue of another protein (usually a lysine) via a covalent isopeptide bond. This effectively tags the second protein, making it distinguishable to other biomolecules and in many cases allowing it to participate in specific reactions or to interact with specific protein complexes. SUMOlyation is closely related to ubiquitination, relying on the same E1/E2/E3 enzymes to transfer SUMO to specific recognition motifs in the target protein, though detaching SUMO depends on SUMO-specific proteases. It plays important roles in numerous cellular processes, including protein localization, transcriptional regulation, stress-response pathways, and cell cycle checkpoints, among others. SUMOlyation is also used in the laboratory as a molecular label and to help solubilize proteins which are difficult to purify.
=== Nobel Prize === The Nobel Committee reacted almost immediately to the first successful clinical trials. In the autumn of 1923, Banting and Macleod received the Nobel Prize in Physiology or Medicine, even though the long-term importance of the discovery was not yet apparent. They were nominated by the Danish physiologist and Nobel laureate August Krogh, who had a diabetic wife and had visited Macleod's laboratory and taken the method back to Denmark. Banting "had well-placed friends in Toronto" and "knowing that a Nobel Prize might well be awarded for insulin, they worked very hard to have Banting honoured, at home and abroad, as the discoverer of insulin". However, "among experienced scientists there was more support for the view that Banting and Best’s somewhat fumbling researches would not have reached the goal without the contributions of both Macleod and Collip". The committee judged that Macleod's work in interpreting the data, managing the clinical trials and providing a high level of public presentation were crucial for success, and "concluded that Banting would not have found the way to insulin without the guidance of Macleod", so they awarded the Nobel prize to both. Banting was furious, as he was convinced that Best should have received the other half, and he even thought of rejecting the prize. He was finally persuaded to accept it but gave half of his prize money to Best. Macleod in turn gave half of his to Collip. In 1972 the Nobel Foundation officially conceded that omitting Best was a mistake.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.